Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension
J. Clin. Invest. Ventzislav Petkov, et al. 111:1339 doi:10.1172/JCI17500 [
Go to this article.]
Figure 7Basal proliferation of PASMCs by VIP. VIP inhibited basal proliferation of PASMCs from PPH patients. This inhibitory effect was dose dependent.
